Venus Remedies Ltd
NSE:VENUSREM
Relative Value
The Relative Value of one
VENUSREM
stock under the Base Case scenario is
667.71
INR.
Compared to the current market price of 758.55 INR,
Venus Remedies Ltd
is
Overvalued by 12%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
VENUSREM Competitors Multiples
Venus Remedies Ltd Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IN |
|
Venus Remedies Ltd
NSE:VENUSREM
|
10.1B INR | 1.5 | 14.4 | 8.9 | 12 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
997.2B USD | 15.3 | 48.3 | 32.5 | 34.6 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
578.6B USD | 6.1 | 21.6 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
281.1B CHF | 4.6 | 30 | 12.7 | 14.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
303.5B USD | 4.7 | 16.6 | 10.4 | 12.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
230.9B CHF | 5.3 | 21.2 | 13.1 | 16.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.1B GBP | 5.2 | 32.1 | 15.3 | 22.4 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK | 4.2 | 12.7 | 9.3 | 11 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.7B USD | 2.5 | 19.9 | 7.4 | 9.9 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.6B USD | 2.6 | 20.8 | 7.3 | 9.6 |